It’s only a matter of time before a pharmaceutical company breaks through with audiences through an award-winning Instagram story or an ephemeral Snap.
Despite being makers, innovators and even at times magicians (e.g. enabling patients to use the immune system – the “Force” within – in order to conquer an ailment or illness), beyond a few exceptions, pharmaceutical companies have largely been laggards when it comes to adopting social and digital communications. Certainly, there’s a robust pipeline of reasons for why pharmaceutical companies have been slow to evolve: from hurdles in digital transformation (e.g. cultural issues, archaic IT systems, limited digital skills, or a lack of clear leadership vision) to the perceived risks associated with breaking from traditional tactics in favor of digital-first approaches. That said, a survey from earlier this year found that 18 percent of healthcare companies planned on increasing their traditional consumer advertising spend, whereas 50% reported planning to increase their digital spend.